A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy.

Leukemia · 2021 · PMC7303943 · PMID 32561840

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

TCP levels in plasma of responding patients showed a trend to higher levels than in primary progressive patients whereas patients with stable disease showed intermediate TCP levels (Fig. 5 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.